In advanced NSCLC patients without prior systemic therapy with high tumour PD-L1 expression, frontline pembrolizumab without chemotherapy led to objective response in 43% with a median progression-free survival of 10.3 months and median overall survival of 26 months. Here, CD274 is linked to neoplasm.